Today we accumulated more shares of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Folks, you’ve gotta buy this stuff when it’s on sale. Read why we invest in FBT right here: 4 Best Long-Term Performance Health Sector ETFs 1.4
Accumulated Health Sector Equities Today (FBT) 9-15-20
Today we accumulated more shares of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Folks, you’ve gotta buy this stuff when it’s on sale. Read why we invest in FBT right here: 4 Best Long-Term Performance Health Sector ETFs 1.4
First Trust expands thematic ETF range with double launch (FBT now available on London Stock Exchange)
First Trust expands thematic ETF range with double launch – ETF Stream
— Read on www.etfstream.com/news/11601_first-trust-expands-thematic-etf-range-with-double-launch/
Trimmed Profits in our Health Sector Equities Today (FBT) 11-25-19
Today we trimmed some profits in our First Trust NYSE Arca Biotechnology Index Fund (FBT) holdings. Buy 92.64. Sell 143.48. Read why we invest in FBT right here: Best Long-Term Performance Health Sector ETFs 1.3
Trimmed Some Profits in our Health Sector ETF (FBT) 11-1-19
Yesterday we trimmed some profits in our First Trust NYSE Arca Biotechnology Index Fund (FBT) holdings. Buy 90.76. Sell 132.43. Read why we invest in FBT right here: Best Long-Term Performance Health Sector ETFs 1.3
Accumulated Biotech Equities Today (FBT) 10-18-19
Today we started a new position in the First Trust NYSE Arca Biotechnology Index Fund (FBT). Folks, you’ve gotta buy this stuff when it’s on sale. Read why we invest in FBT right here: Best Long-Term Performance Health Sector ETFs 1.3
4 Best Long-Term Performance Health Sector ETFs 1.3
Is the Health Sector a good place to invest?
The Health Care Select Sector SPDR® Fund (XLV) is the oldest and largest Health Sector ETF available. Its’ inception date was on December 16, 1998.
XLV vs S&P 500 index fund: January 1999 – August 2019
Source: https://www.portfoliovisualizer.com/
XLV vs SPY: December 22, 1998 – September 6, 2019
Source: https://www.koyfin.com/home Continue reading “4 Best Long-Term Performance Health Sector ETFs 1.3”
The Best ETF To Play Biotech (FBT)
Summary
- Big pharma stocks have underperformed and are likely to continue buying biotech companies for growth.
- The charts also show large cap biotech companies are underperforming their mid/small cap counterparts.
- The potential for big pharma and large cap biotech companies looking for needle moving companies points to mid-cap biotech companies being attractive targets for both.
- Not surprisingly, the biotech ETF with the largest exposure to mid-cap biotech companies has the best performance over the past 1-, 2-, 3- and 5-year periods.
The recently announced deal of Bristol-Myers Squibb (BMY) acquiring Celgene (CELG) got me thinking about biotech & big pharma stocks. The following chart perfectly sums up why I believe big pharma will continue to be acquirers of large-cap biotech companies and small/mid cap companies. Slowing growth due to generic competition and increased scrutiny of drug prices has caused shares of big pharma companies to underperform biotechs and the overall healthcare sector. As you can see below, big pharma as represented by the SPDR S&P Pharmaceuticals ETF (XPH), has gone nowhere since the beginning of 2016, while biotech as represented by the SPDR Biotech ETF (XBI) is up substantially, as is the Health Care Select Sector SPDR ETF (XLV). Simply put, given this vast underperformance, I expect big pharma to go on a spending spree to buy future growth and I will be detailing the current ETF options available in the biotech sector.
Continue reading at Seeking Alpha right here: https://seekingalpha.com/article/4238204-best-etf-play-biotech
Best Long-Term Performance Health Sector ETFs 1.2
- The oldest Health Sector ETF has outperformed an S&P 500 index fund by 1.90% CAGR over the last 19 years. This Health Sector ETF has also experienced less volatility than an S&P 500 index fund.
- There are currently 35 ETFs in the Morningstar Category called Health. 16 of these funds are 10 years old or older.
- The top performing Health Sector ETF has outperformed an S&P 500 index fund by 8.98% CAGR over the last 12 years.
Health Care Select Sector SPDR® Fund (XLV) vs S&P 500 index fund: January 1999 – September 2018
Source: https://www.portfoliovisualizer.com/
Continue reading “Best Long-Term Performance Health Sector ETFs 1.2”
Top ETFs: First Trust Biotech ETF Beats Larger RivalsTop ETFs: First Trust Biotech Beats Larger Rivals (FBT) | Investor’s Business Daily
Smaller is better for First Trust NYSE Arca Biotechnology Index Fund, which has become one of the top ETFs by using a concentrated portfolio.
— Read on www.investors.com/etfs-and-funds/etf-leaders/top-etfs-first-trust-biotech/
Smaller Is Better For First Trust Biotech ETF, Which Is Up More Than 20% In 2018 (FBT)
The biotech ETF is up more than 20% this year, earning a spot on IBD’s ETF Leaders screen. It’s done that with a portfolio that’s concentrated on just 30 holdings.
— Read on www.investors.com/etfs-and-funds/etf-leaders/biotech-etf-first-trust-nyse-biotechnology-index-fund/
Adding Biotech ETFs to Your Portfolio | (FBT) Investopedia
Biotech ETFs are among the most popular investment vehicles. Here are some reasons for why they’re worth considering.
— Read on www.investopedia.com/investing/adding-biotech-etfs-your-portfolio/
Adding Biotech ETFs to Your Portfolio | (FBT) Investopedia
Biotech ETFs are among the most popular investment vehicles. Here are some reasons for why they’re worth considering.
— Read on www.investopedia.com/investing/adding-biotech-etfs-your-portfolio/
The 4 Top Biotech ETFs – Motley Fool (FBT)
“Biotechnology has been on the cutting edge of healthcare for years, and countless new treatments have made life better for millions of people across the globe. Investing in biotechnology companies can be extremely risky, because the success or failure of a single candidate treatment can make or break the company’s entire future.”
Continue reading at Yahoo Finance: The 4 Top Biotech ETFs
Don’t Bail On Biotech ETFs: ‘There Are Several Reasons Why The Sector Took A Breather’ – MarketWatch
Don’t Bail On Biotech ETFs (FBT): ‘There Are Several Reasons Why The Sector Took A Breather’ – MarketWatch
Trimmed Some Profits In Biotech Today (FBT) 1-26-18
We trimmed some more profits off of our biotech holdings today. (FBT) First Trust NYSE Arca Biotechnology Index Fund. Price paid $92.38. Price sold $145.38. Read why we invest in FBT right here: Discovering Value in Growth Stock Funds: Biotech ETFs
Trimmed Some Profits In Biotech (FBT) 1-22-18
Trimmed some profits in the First Trust NYSE Arca Biotechnology Index Fund (FBT). Price paid $90.76. Price sold $141.11. Read why we invest in FBT right here: Discovering Value in Growth Stock Funds: Biotech ETFs
Trimmed Some Profits Off Our Biotech Holdings (FBT) 1-9-18
Biotechs are zooming again. We trimmed some more fat from our biotech holdings today. I still believe the First Trust NYSE Arca Biotechnology Index Fund (FBT : $FBT) is a great investment. You can read why we invest in FBT right here: Discovering Value in Growth Stock Funds: Biotech ETFs. Price paid $92.38. Price sold $129.68.
Trimmed Some Fat Off Our Biotech Holdings Today (FBT) 10-16-17
We trimmed some fat off our Biotech holdings today. First Trust NYSE Arca Biotechnology Index Fund (FBT : $FBT) is still a great ETF; we’re just taking some profits off the table. Price paid $91.61. Price sold $127.58.
Here’s what I wrote about the Biotech sector in January 2017: Discovering Value in Growth Stock Funds: Biotech ETFs
Sold Some Of Our Biotech Equity Holdings Today (FBT)
We sold some of our Biotech holdings today. I don’t currently see any problems in this is industry or this particular ETF at this time. We only sold to use the funds in another endeavor. Price paid $89.36, price sold $117.12. The First Trust NYSE Arca Biotechnology Index Fund (FBT : $FBT) is still a great fund and I still recommend it to other investors. I wrote about FBT back in January 2017 and updated the charts in the article in May 2017 right here: Discovering Value in Growth Stock Funds: Biotech ETFs
Trimmed Some Fat Off Our Biotech Equities Today (FBT)
We sold some of our Biotech equities today. (FBT : $FBT) No problem with the First Trust NYSE Arca Biotechnology Index Fund (FBT); just taking some profits off the table. Price paid $91.89. Price sold $119.87.
Here’s an article I wrote about FBT back in January 2017: Discovering Value in Growth Stock Funds: Biotech ETFs
The Zacks Analyst Blog Highlights: First Trust NYSE Arca Biotechnology Index Fund (FBT)
Are Biotech Funds Buys Once Again?
Are Biotech Funds Buys Once Again?
While a number of market industries were fearful of a Trump Presidency, nowhere was the concern more prevalent than in the biotech and drug segment. After all, Trump came out several times against the pricing practices in the drug market, vowing to do something to make this a more affordable area…. (Read full article at Zacks.)
FBT’s Underlying Holdings Could Mean 11% Gain Potential (FBT)
Check out this article about First Trust NYSE Arca Biotechnology Index Fund (FBT : $FBT) at NASDAQ: FBT’s Underlying Holdings Could Mean 11% Gain Potential